or Try an Advanced Search...

    Technical Analysis for APLM - Apollomics Inc.

    Grade Last Price % Change Price Change
    F 0.41 2.66% 0.01
    APLM closed up 2.66 percent on Wednesday, May 8, 2024, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical APLM trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    180 Bearish Setup Bearish Swing Setup 2.66%
    Narrow Range Bar Range Contraction 2.66%
    Wide Bands Range Expansion 2.66%
    Oversold Stochastic Weakness 2.66%
    Hammer Candlestick Bullish -1.60%
    Older End-of-Day Signals for APLM ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 12 hours ago
    Possible Inside Day about 12 hours ago
    1.5x Volume Pace about 16 hours ago
    Up 3% about 17 hours ago
    Up 2% about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    APLM Chart by TradingView
    Basic chart:

    Profile

    Apollomics Inc. Description

    Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Acute Myeloid Leukemia Chemotherapy Non Small Cell Lung Cancer Antineoplastic Drugs Leukemia Targeted Therapy Treatment Of Non Small Cell Lung Cancer Hematologic Cancers Oncology Therapies Phosphoinositide 3 Kinase Inhibitor

    Is APLM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Apollomics Announces Private Placement Financing and Addition to Board of Directors
    Apr 25 Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
    Apr 10 Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    Apr 2 Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    Mar 28 Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript
    Mar 28 Apollomics GAAP EPS of -$2.32
    Mar 28 Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
    Mar 26 Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
    Mar 4 Apollomics Names Matthew Plunkett as Chief Financial Officer
    Mar 4 Apollomics appoints CFO
    See more APLM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.45
    52 Week Low 0.388
    Average Volume 182,102
    200-Day Moving Average 1.81
    50-Day Moving Average 0.58
    20-Day Moving Average 0.47
    10-Day Moving Average 0.42
    Average True Range 0.05
    RSI (14) 32.43
    ADX 31.89
    +DI 11.57
    -DI 21.55
    Chandelier Exit (Long, 3 ATRs) 0.46
    Chandelier Exit (Short, 3 ATRs) 0.53
    Upper Bollinger Bands 0.58
    Lower Bollinger Band 0.36
    Percent B (%b) 0.24
    BandWidth 46.63
    MACD Line -0.05
    MACD Signal Line -0.05
    MACD Histogram -0.0002
    Fundamentals Value
    Market Cap 36.97 Million
    Num Shares 89.5 Million
    EPS -4.34
    Price-to-Earnings (P/E) Ratio -0.10
    Price-to-Sales 49.74
    Price-to-Book 1.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.44
    Resistance 3 (R3) 0.44 0.43 0.43
    Resistance 2 (R2) 0.43 0.42 0.43 0.43
    Resistance 1 (R1) 0.42 0.42 0.43 0.42 0.43
    Pivot Point 0.41 0.41 0.41 0.41 0.41
    Support 1 (S1) 0.40 0.41 0.41 0.40 0.39
    Support 2 (S2) 0.40 0.40 0.40 0.39
    Support 3 (S3) 0.39 0.40 0.39
    Support 4 (S4) 0.39